Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Estoppey, David ^a   Hewett, Jeffrey W ^b   Guy, Chantale T ^b   Harrington, Edmund ^b   Thomas, Jason R ^b   Schirle, Markus ^b   Cuttat, Rachel ^a   Waldt, Annick ^a   Gerrits, Bertran ^a,c   Yang, Zinger ^b   Schuierer, Sven ^a   Pan, Xuewen ^b   Xie, Kevin ^b   Carbone, Walter ^a   Knehr, Judith ^a   Lindeman, Alicia ^b   Russ, Carsten ^b   Frias, Elizabeth ^b   Hoffman, Gregory R ^b   Varadarajan, Malini ^b   Ramadan, Nadire ^b   Reece Hoyes, John S ^b   Wang, Qiong ^b   Chen, Xin ^b   McAllister, Gregory ^b   Roma, Guglielmo ^a   Bouwmeester, Tewis ^a   Hoepfner, Dominic ^a   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CRISPR CAS SYSTEM; DRUG DEVELOPMENT; DRUG EFFECT; GENE DELETION; GENETICS; HUMAN; INDUCED PLURIPOTENT STEM CELL; METABOLISM; PHARMACOGENETIC TESTING; PROCEDURES;

CELLS, CULTURED; CRISPR-CAS SYSTEMS; DRUG DISCOVERY; ENZYME INHIBITORS; GENE DELETION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHARMACOGENOMIC TESTING;

EID: 85012951126     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42728     Document Type: Article

References (18)

1. Giaever, G. et al. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nature genetics 21, 278-283 (1999).
2. Lee, A. Y. et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science 344, 208-211 (2014).
3. Hoepfner, D. et al. High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions. Microbiological research 169, 107-120 (2014).
4. Schmitt, E. K., Hoepfner, D. & Krastel, P. Natural products as probes in pharmaceutical research. J Ind Microbiol Biotechnol 43, 249-260 (2016).
5. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
6. Brattain, M. G., Fine, W. D., Khaled, F. M., Thompson, J. & Brattain, D. E. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 41, 1751-1756 (1981).
7. Brodsky, R. A. How I treat paroxysmal nocturnal hemoglobinuria. Blood 113, 6522-6527 (2009).
8. Konig, R. et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods 4, 847-849 (2007).
9. Nahimana, A. et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 113, 3276-3286 (2009).
10. Hart, T. et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell 163, 1515-1526 (2015).
11. Takahashi, R. et al. Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase. J Biochem 147, 95-107 (2010).
12. Wang, W. et al. Structural basis for resistance to diverse classes of NAMPT inhibitors. PloS one 9, e109366, doi: 10. 1371/journal. pone. 0109366 (2014).
13. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
14. Menssen, A. et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA 109, E187-196 (2012).
15. Tateishi, K. et al. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22, 4452-4465 (2016).
16. Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E. & Dang, C. V. MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43, 11-21 (2015).
17. Matheny, C. J. et al. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens. Chemistry & biology 20, 1352-1363 (2013).
18. Deans, R. M. et al. Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification. Nat Chem Biol 12, 361-366 (2016).